Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

node positive breast cancer randomized between anastrozole/letrozole 5 years and anastrozole/letrozole 2-3 years switching to exemestane 3-2 years.

lumpectomy
invasive carcinoma
endocrine therapy
carcinoma
adjuvant therapy
  • 0 views
  • 07 Nov, 2020
  • 1 location
Pulmonary Hypertension and Anastrozole Trial

The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side

pulmonary disease
interstitial lung disease
heart disease
left ventricular end-diastolic pressure
connective tissue disease
  • 72 views
  • 25 Jan, 2021
  • 7 locations
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

luteinizing hormone
serum luteinizing hormone
anastrozole
letrozole
aromatase inhibitor
  • 38 views
  • 08 Nov, 2020
  • 1 location
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)

This is a randomized study comparing the use of Anastrozole before and continuing during radiotherapy for breast cancer compared to the use of anastrozole after irradiation.

lumpectomy
progesterone receptor
estrogen
anastrozole
mastectomy
  • 51 views
  • 07 Nov, 2020
  • 3 locations
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

are exemestane, anastrozole, letrozole. The purpose of this study is to find out whether it is better to receive exemestane, anastrozole, or letrozole to improve the chance that the

hormone therapy
estrogen
exemestane
anastrozole
letrozole
  • 6 views
  • 07 Nov, 2020
  • 1 location
ATRA Trial - ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER eBC ATRA TRIAL

contributes to tumor regression in a specific sub-population of eBCs. Using a preoperative "window-of-opportunity" model, aimed at testing the activity of ATRA in combination with anastrozole in

  • 0 views
  • 23 Jan, 2021
  • 1 location
CB-103 Plus NSAI In Luminal Advanced Breast Cancer

-steroidal aromatase inhibitor (NSAI), anastrozole or letrozole, in Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer patients who have achieved

  • 0 views
  • 29 Apr, 2021
  • 15 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

progesterone receptor
metastasis
HER2
measurable disease
her2-negative breast cancer
  • 0 views
  • 18 Apr, 2021
  • 49 locations
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of

  • 0 views
  • 31 May, 2021
  • 137 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

endocrine therapy
gnrh
HER2
fulvestrant
invasive breast cancer
  • 0 views
  • 24 May, 2021
  • 69 locations